Compare CTRA & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRA | RVMD |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 19.1B |
| IPO Year | 1994 | N/A |
| Metric | CTRA | RVMD |
|---|---|---|
| Price | $34.90 | $96.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $35.27 | ★ $120.47 |
| AVG Volume (30 Days) | ★ 10.2M | 1.6M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 49.33 | N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $7,645,000,000.00 | N/A |
| Revenue This Year | $12.95 | N/A |
| Revenue Next Year | $7.21 | $408.69 |
| P/E Ratio | $15.44 | ★ N/A |
| Revenue Growth | ★ 40.07 | N/A |
| 52 Week Low | $22.33 | $29.98 |
| 52 Week High | $36.88 | $124.49 |
| Indicator | CTRA | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 46.18 |
| Support Level | $23.03 | $93.39 |
| Resistance Level | $36.88 | $107.45 |
| Average True Range (ATR) | 1.08 | 3.09 |
| MACD | -0.12 | 0.17 |
| Stochastic Oscillator | 51.10 | 41.98 |
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.